MedPath

Comparison Study of the Different Abbreviated Versions of the Geriatric Depression Scale

Completed
Conditions
Depressive Disorder
Neurocognitive Disorders
Dementia
Depression
Interventions
Other: Battery of screening tests with semi-structured interview
Other: Battery of screening tests without semi-structured interview
Registration Number
NCT04180683
Lead Sponsor
Rsocialform - Geriatria, Lda
Brief Summary

This multicenter study conducted in several Portuguese institutions aims to compare the screening ability of the several Geriatric Depression Scale (GDS) validated versions for the Portuguese population (GDS-30, GDS-15, GDS-10 and GDS-5), as well as to establish their psychometric properties, using a large sample of elderly people with neurocognitive disorders attending social responses addressed to the elderly. Secondarily, cognitive state will be assessed.

Detailed Description

Depression is the most common mental health problem among older people, both in Portugal and around the world. Due to the fast aging of the world population, depression is a significant problem, with an estimated prevalence between 8% and 16%, which is more common in institutionalized elderly. Several studies have shown the negative consequences of depression in the elderly, which has been associated with higher morbidity and mortality rates, increased use of health services and increased costs. In addition, older people's depression is associated with major disability, chronic health problems, higher suicide rates, dementia and a lower quality of life. However, it is often an unrecognized, and therefore untreated, problem.

Under these circumstances, screening people at risk of depression (people with chronic illness, stroke, dementia, institutionalized or attending social responses, etc.) is a strategy with potential to reduce the impact of depression among the elderly.

One of the most commonly used screening scales for depressive symptoms in elderly is the Geriatric Depression Scale (GDS), a widely known and widely used scale designed specifically for older people. For this reason, it does not include questions related to somatic symptoms, as they lack discriminatory value in older people, because they can be attributed to other physical conditions or the aging process. The original version of the scale is composed by 30 items with a dichotomous response (yes/no) assessing motivation, energy, past and future orientation, mood, cognitive complaints, anxiety and irritability. The GDS scale has good psychometric properties and has been evaluated in a wide range of geriatric populations, institutionalized patients, elderly with chronic health problems, people with dementia, etc. In order to achieve better time efficiency in its administration, the original 30-item scale was abbreviated to a 15-item version. Posteriorly, multiple shorter versions of this scale were developed, composed by one, four, five, ten or twelve items.

The GDS scale has been widely translated and validated worldwide. In Portugal, the GDS-30 was adapted and validated by Pocinho, Farate, Dias, Lee and Yesavage. The versions of GDS-15, GDS-10 and GDS-5 were adapted and validated by Apóstolo and colleagues having demonstrated good psychometric properties and, therefore, potential as a screening tool for depressive symptoms in older people.

The aim of this study is to compare the screening ability of the several validated versions for the Portuguese population of the GDS scale (GDS-30, GDS-15, GDS-10 and GDS-5), as well as to establish their psychometric properties, using a large sample of elderly patients attending social responses addressed to the elderly. This study will allow recommendations on which is the most sensitive GDS version for detecting depressive symptoms by comparing them with other depression screening scales.

To achieve this, the results of the several GDS versions will be compared with the application of a gold standard, the Beck-II Depression Inventory \[BDI-II\].

Regarding the BDI-II, it is important to mention its good psychometric characteristics when used in the elderly population, which were evident in studies that compared the psychometric characteristics of different scales used to assess depression in the elderly. I was concluded that this instrument obtained a test-retest value of 0.93, Cronbach's α ranged from 0.76 to 0.91 in elderly Americans, in a community-dwelling elderly, in Puerto Rican residents, in elderly with heart problems, and in women living in institutions for the elderly. In elderly clinical samples, Cronbach's α ranged from 0.89 to 0.92. BDI is significantly and positively correlated with CES-D (r = 0.69, p \<0.001) and with GDS (r = 0.71, p \<0.001). The clinical utility of BDI-II is proven and high because of its clinical sensitivity and consistency with the DSM-IV criteria. In addition, it identifies many depressive symptoms and is one of the most commonly used instruments in the elderly without cognitive decline and also in non-clinical samples, as it is brief and easily administered and scored.

On the other hand, in another study where BDI-II was applied to elderly people with cognitive deficits, it was found that this population has symptoms similar to those of young people and adults, supporting the validity of this instrument in this population.

In order to reinforce the assessment of the screening ability of the several GDS versions validated for the Portuguese population, as well as to establish their psychometric properties, a sample (estimated at about 25%) will be defined, in which the GDS will be compared with a gold standard, that will consist of a semi-structured interview guide based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders (5th ed.) for depressive disorders. For this sample, a questionnaire will be answered by the professionals who perform the evaluation, regarding their opinion about which GDS version is more easily understandable by the participants and the participants' preference regarding the different versions of GDS, as a means of assessing which version is more discernible for the participants. All the GDS versions validated for the Portuguese population (GDS-30, GDS-15, GDS-10 and GDS-5) will be administered to these participants.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
331
Inclusion Criteria
  • Having a diagnosis of neurocognitive disorder according to the DSM-5 criteria and based on the MMSE scores.
  • To be able to understand and answer the instruments' questions.
  • Being 65 years of age or older.
  • Being a native Portuguese speaker.
  • To attend a social response addressed to the elderly in an institution.
Exclusion Criteria
  • Having severe sensory and physical limitations, severe disconnection from the environment, or presence of severe neuropsychiatric symptoms that make it impossible to administer the assessment battery.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Semi-structured interview groupBattery of screening tests with semi-structured interviewParticipants assigned to this group will be administered the GDS-30, GDS-15, GDS-10 nad GDS-5, and also the BDI-II and a semi-structured interview based on the DSM-5 criteria. The psychologists performing the assessment will answer a questionnaire about which GDS version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
No semi-structured interview groupBattery of screening tests without semi-structured interviewParticipants assigned to this group will be administered the GDS-30 and the GDS-15, and also the BDI-II.
Primary Outcome Measures
NameTimeMethod
Depressive symptomatology assessed through the GDS-15Baseline

Participants' scores in the GDS-15. This instrument evaluated depressive symptoms using yes/no answers. Scores range between 0 and 15 points. Higher scores indicate more severe depressive symptoms.

Depressive symptomatology assessed through the GDS-10Baseline

Participants' scores in the GDS-10. This instrument evaluated depressive symptoms using yes/no answers. Scores range between 0 and 10 points. Higher scores indicate more severe depressive symptoms.

Depressive symptomatology assessed through the GDS-5Baseline

Participants' scores in the GDS-5. This instrument evaluated depressive symptoms using yes/no answers. Scores range between 0 and 5 points. Higher scores indicate more severe depressive symptoms.

Depressive symptomatology assessed through the BDI-IIBaseline

Participants' scores in the BDI-II. This instrument evaluates depressive symptoms. Scores range from 0 to 63 points. Higher scores indicate more severe depressive symptoms.

Depressive symptomatology assessed through the GDS-30Baseline

Participants' scores in the GDS-30. This instrument evaluated depressive symptoms using yes/no answers. Scores range between 0 and 30 points. Higher scores indicate more severe depressive symptoms.

Depressive symptomatology assessed through the semi-structured interviewBaseline

Participants' answers in the semi-structured interview. This interview includes questions regarding depressive symptomatology and is based on the DSM-5 criteria.

Secondary Outcome Measures
NameTimeMethod
Acceptability of the instruments by the participants evaluated though the questionnaire applied to the psychologistsBaseline

Psychologists answers in the questionnaire, designed specifically for this study. It will allow to understand which version is more easily understandable by the participants and their preference regarding the GDS versions. This questionnaire will only be answered by the clinical psychologists that conducted the evaluation sessions with the participants in the Semi-structured interview group.

Cognitive state evaluated through the Mini-Mental State ExaminationBaseline

Participants' scores/answers in the MMSE that will allow to understand if the participants meet the inclusion criteria. MMSE is a brief cognitive screening test. Scores range between 0 - 30 points. Higher scores indicate better cognitive function. MMSE will be administered to all participants.

Trial Locations

Locations (32)

Centro de Assistência Paroquial da Pampilhosa

🇵🇹

Mealhada, Aveiro, Portugal

Fundação Luiz Bernardo de Almeida

🇵🇹

Vale de Cambra, Aveiro, Portugal

Lar D. Pedro V

🇵🇹

Praia da Vitória, Açores, Portugal

Centro Social e Paroquial de S. Martinho de Medelo

🇵🇹

Fafe, Braga, Portugal

Lar de S. José

🇵🇹

Covilhã, Castelo Branco, Portugal

Fundação Sarah Beirão/António Costa Carvalho

🇵🇹

Tábua, Coimbra, Portugal

PRODECO - Progresso e Desenvolvimento de Covões

🇵🇹

Cantanhede, Coimbra, Portugal

Fundação AFID Diferença

🇵🇹

Amadora, Lisboa, Portugal

Associação de Solidariedade Social de Ponte de Sôr

🇵🇹

Ponte de Sôr, Portalegre, Portugal

Santa Casa da Misericórdia de Caminha

🇵🇹

Caminha, Viana Do Castelo, Portugal

Centro Social e Paroquial de S. Vicente de Alcabideche

🇵🇹

Alcabideche, Lisboa, Portugal

Santa Casa da Misericórdia de Ferreira do Alentejo

🇵🇹

Ferreira do Alentejo, Beja, Portugal

Cediara - Associação de Solidariedade Social de Ribeira de Fráguas

🇵🇹

Albergaria-a-Velha, Aveiro, Portugal

Santa Casa da Misericórdia de Melgaço

🇵🇹

Melgaço, Viana Do Castelo, Portugal

Rsocialform - Geriatria, Lda.

🇵🇹

Mealhada, Aveiro, Portugal

Fundação João Bento Raimundo

🇵🇹

Guarda, Portugal

Santa Casa da Misericórdia de Alcobaça

🇵🇹

Alcobaça, Leiria, Portugal

Santa Casa da Misericórdia de Alvorge

🇵🇹

Ansião, Leiria, Portugal

Santa Casa da Misericórdia de Arronches

🇵🇹

Arronches, Portalegre, Portugal

Centro Social Paroquial de Recarei

🇵🇹

Paredes, Porto, Portugal

Santa Casa da Misericórdia de Tarouca

🇵🇹

Tarouca, Viseu, Portugal

Santa Casa da Misericórdia de Vouzela

🇵🇹

Vouzela, Viseu, Portugal

Irmãs Hospitaleiras - Casa de Saúde da Idanha

🇵🇹

Sintra, Lisboa, Portugal

Santa Casa da Misericórdia de Castelo Branco

🇵🇹

Castelo Branco, Portugal

Cáritas de Coimbra

🇵🇹

Coimbra, Portugal

Santa Casa da Misericórdia de Arez

🇵🇹

Nisa, Portalegre, Portugal

Santa Casa da Misericórdia de Canha

🇵🇹

Montijo, Setúbal, Portugal

Centro Social Vale do Homem

🇵🇹

Vila Verde, Braga, Portugal

Santa Casa da Misericórdia do Fundão

🇵🇹

Fundão, Castelo Branco, Portugal

Quintinha da Conceição Sousa & Silva Lda

🇵🇹

Maia, Porto, Portugal

Associação de Desenvolvimento da Vila de Paço Sousa

🇵🇹

Penafiel, Porto, Portugal

Centro Social de Bem-Estar de Alcanena

🇵🇹

Alcanena, Santarém, Portugal

© Copyright 2025. All Rights Reserved by MedPath